Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"In exchange for the extensions"
So if the lender Converts after 2 years the Issuance Conversion Rate remains in place.
This makes perfect sense as lenders take a risk in committing their money for 2 years and in the Penny Stock market it is a larger risk given the high percentage of Penny Stock companies that fail. If they are going to leave their money at risk for an additional 2 years there should be an adjustment.
I actually think the Conversion Rate being based on the Conversion Date is an excellent deal for a Profitable BIEL.
If I enter into a Conversion Loan today with BIEL at .0005 my Conversion Rate would be .00025. If BIEL is trading at .005 in two years on my Conversion Date I receive an enormous profit.
The lenders who Extended their loans and went to the 'Conversion Rate at Conversion Date' are capped at a 50% Conversion bonus..
This has major implications for a Profitable BIEL. At a .00025 Conversion Rate it would take north of 40 billion shares to pay off BIEL's Convertible Loans. At a SP of 1 cent and a Conversion Rate, .005, established on the Conversion Date it would only take 2 billion shares to pay off the same debt.
And your proof of that Opinion.... because until documentation is provided it is just an Opinion
The only statement found in the financials,
"The conversion prices on the convertible notes payable have generally been 50% or less of the pink sheet closing price of the common stock on the date the notes or advances are issued"
People keep bringing up 50% discount at conversion
When I read the financials this is what BIEL states about convertible loans;
"The conversion prices on the convertible notes payable have generally been 50% or less of the pink sheet closing price of the common stock on the date the notes or advances are issued to reflect the restricted nature of the stock into which the notes could be converted and the Board of Directors’ belief that the closing stock price is not reflective of the fair market value of the common stock due to the price volatility, and lack of an active market for trading shares resulting in limited trading volume of share transactions. The Board of Directors is active in negotiating conversion prices for each issuance and takes into consideration all information in establishing the issuance date fair market value."
So, 50% or less at the Issuance Date SP not the Conversion Date, with BIEL willing to negotiate if the Conversion Date SP is significantly lower than the Issuance Date SP.
From the BIEL Q3 2022 Disclosure Statement, this policy demonstrated;
"During the second quarter of 2018, the Company entered into a convertible note agreement with Abhinav Humar, receiving financing of $160,000, with an interest rate of 8% per annum and convertible at a rate of $.0013 per share. The balance on this loan was $224,450 as of September 30, 2022."
This loan was Issued on 5/18/2018. BIEL's SP ranged from a high of .0031 to a low of .0021 during this week.
Reading Material for you re dilution concerns:
Sunday, October 23, 2022 11:29:10 AM
Post# 301191
Several Very Large Holes in that Opinion
Convertible Note Holders have to Convert their Loans to Shares before they can Sell
BIEL has only 295 million shares available to pay back Convertible Note Holders with before they hit their 'Authorized Share' limit
All of BIEL's current Convertible Loans are with 'Friendly Lenders' who have rolled over their Loans in the past, IBEX, St John's, Dr Staelin, T. Kim, Jarman
Since Dr Staelin rejoined BIEL as COB in 2020 all of his many Loans to BIEL have been Principle & Interest only, No Conversion option
St John's also switched to Principle & Interest Loans in January 2022
Tuesday, November 15, 2022 3:43:17 PM
Post# 302216
BIEL showed 24.705 billion shares outstanding in the Q1 2022 Financials
BIEL showed 24.705 billion shares outstanding in the Q3 2022 Financials.
That is zero dilution in Q2 and again in Q3 2022.
St John's has made $91k in Interest Only Loans to BIEL in 2022.
Dr. Staelin has made $535k in Interest Only Loans to BIEL since he returned to the COB position in 2020.
Erin Sanders made a $25k Interest Only Loan to BIEL in Q3 2022.
IBEX and St John's have saved BIEL $2.5 million by foregoing the interest on their loans over the last several years.
Everyone at BIEL is serious about controlling dilution and bringing BIEL to profitability.
Saturday, November 19, 2022 10:35:50 AM
Post# 302488
The Disclosure Statements also show that Dr Staelin's last conversion was over 3 years ago in September 2019
He has been Rolling Over his convertible loans for another 2 years since he took over the COB position in 2020.
He has made over $500k in new loans since 2020 and they are all Interest Only loans, no conversion option.
Disclosure shows that the last conversion by BIEL's CEO was in March of 2019. She has Rolled Over dozens of convertible loans for another 2 years saving BIEL billions of shares in dilution.
BIEL's CEO has also foregone millions of dollars of interest, which means canceling it not delaying it, to help BIEL reach profitability sooner.
Only 5 million shares remain on the 5 Ask
Bid size = 110 million shares
Buys = 23 million shares
Sells = 882k shares
2:38 Update, 5s gone
Adcock Ingram is Serious about Relieving Pain
Pain is the oldest medical problem and the most common reason we seek medical care. It is often classified as acute or chronic depending on how long the pain is present. As pain is a subjective experience, doctors assess pain severity on a rating scale according to personal reports by patients. The World Health Organization (WHO) recommends clinicians treat pain according to a ‘Pain Ladder’, which allocates medication classes according to the severity of the pain – as you go up the ‘pain severity ladder’, different classes of medication are added for pain relief.
Our range of products can be used for acute pain relief or for long-term chronic treatment of various painful conditions including but not limited to: headache with or without tension, low back pain, muscle spasms, inflammatory conditions, sports injuries, dental pain, cancer pain and post-operative pain.
Speak to you pharmacists about the Adcock Ingram's range of products available over the counter. For more severe pain, consult your Doctor for Adcock Ingram's Prescription Pain medication.
BIEL started today with 27 million shares on the 5 Ask
That has now been whittled down to 13.9 million shares.
Buys = 14 million shares
Sells = 842k shares
Thanks JGD and Hawk, We missed a Merry Christmas but will have a Happy New Year
10 Pallets to Adcock Ingram
Go BIEL !!!
Go Adcock Ingram !!!
https://twitter.com/bielcorp
I don't recall anyone at BIEL ever saying that an 11 digit OS count did not need to be addressed
What BIEL has said , both AW and KW, was that once the company was profitable the share count would be addressed. This would be addressing the OS from a position of strength, as a profitable enterprise, verses as a struggling company that could be subjected to Market manipulation. See ENDV as an example of where their 2 Reverse Splits got them and their investors, 1 for 100 and 1 for 1,000 ..
Nope, Scam companies RS every few years to hide their losses
BIEL = zero RS after 20 years.
Scam companies don't have a dozen UCSD Researchers, Surgeons and Anesthesiologists calling for larger Studies on their products.
Scam companies don't have their CEOs foregoing millions of dollars in interest.
Scam companies don't have their CEOs deferring their salary.
Scam biotech companies don't hold 5 FDA 510k Indications for medical conditions.
Scam companies don't have companies the size of STADA and Adcock Ingram signing contracts with them.
No one is happy with the .0004 SP but it has happened several times in BIEL's history as shareholders grow tired of waiting for a material event.
The important thing to remember is that BIEL has always bounced back with significant news and Synergy is by far the Biggest Deal in BIEL's history.
IMO, we see the largest run BIEL has ever had once the Synergy PR is released.
Good Grief, 510k #K192234, 1/31/2020, OTC Musculoskeletal Pain
<<<<<<< Keith said there was a "new 510k" in 2020? Really? For what indication? >>>>>>>
Let me guess, that "Market Research" was conducted by Fantasy 'Sales Track'
Dr Ilfeld knows the process to get large Studies funded
He is highly respected in the research community so when he writes a paper, even if it is just a 'Proof of Concept', Doctors, Researchers and the DOD take notice.
Dr Ilfeld Research Activities And Funding
Eliminating Post-Mastectomy Pain and Opioids with Percutaneous Cryoneurolysis: A Single-Administration, Non-Opioid, Non-Addictive, Multiple-Month Analgesic
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-21-PRMRP-CTA (PR212158)Sep 30, 2022 - Sep 29, 2026
Role: Principal Investigator
Description: $5,290,392
Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacologic Alternative for the Treatment of Postoperative Pain
Department of Defense Congressionally Directed Medical Research Programs, NIH-DoD-VA Pain Management Collaboratory—Pragmatic Clinical Trials Demonstration Projects (UG3/UH3)W81XWH-18-2-0009 (NH170005)May 1, 2018 - Apr 30, 2024
Role: Principal Investigator
Description: $6,971,337
Improving Postamputation Functioning by Decreasing Phantom Limb Pain and Opioid Use With Perioperative Continuous Peripheral Nerve Blocks: A Multicenter RCT
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Orthopaedic Research Program (PRORP)W81XWH-17-1-0671 (OR160012)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $2,847,215
Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-17-2-0051 (PR160263)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $3,950,572
Treating Intractable Post-Amputation Phantom Limb Pain with Ambulatory Continuous Peripheral Nerve Blocks
Department of Defense Congressionally Directed Medical Research Programs Defense Medical Research and Development ProgramW81XWH-13-2-009Jan 25, 2012 - Dec 24, 2020
Role: Principal Investigator
Description: $2,617,000
For those who need reminding of what a scam company looks like....
Our good friends at ENDV are happy to comply.
ENDV purchased a concrete company, with shares as they have no cash, several months ago because concrete and prescription PEMF devices have a lot in common, right.
ENDV just announced that they are splitting off the Sofpulse medical device business into a new company, 'NewCo'. ENDV which currently has a Market Cap of $2.7 million stated the following,
"Management expects on completion of the spinoff, NewCo will have a pre-money valuation of over $50 million. NewCo’s management believes it can take the company to over $100 million in sales by 2024."
This from a company who has never sold more than a few hundred devices per Quarter.
Meanwhile BIEL is actually selling PEMF medical devices, recently signing the largest contract in BIEL's history with Synergy Corp.
https://www.mpo-mag.com/contents/view_breaking-news/2022-12-19/endonovo-to-spin-off-medical-ip-and-assets/24664
Well said Miami
Marketing to a country the size of the US would require a massive Advertising and Distribution budget that BIEL does not have. BIEL got a taste of volume retail selling costs when they were in a couple thousand UK pharmacies. Highest Sales Revenue in BIEL's history but also the highest Net Losses.
Synergy is the Largest Contract in BIEL's history, 25 countries, 975,000 devices over 18 months. It is still happening.
How about some details on that "here it is"
2,000 shares @ .0004
515,000 shares @ .00045
17 million shares @ .0005
Therein lies the rub
<<<<<<<< We've seen it done many times over the last decade or more >>>>>>>
IMO, BIEL has dipped into the 'speculation well' too many times and had their bucket retrieved far from full. They now need to turn one of their regulatory wins into cash to generate significant investor interest.
That is what an opening order of 100k+ RecoveryRx units from Synergy could accomplish.
As far as the "concentrated PR campaign" it would have to be funded by a Partner as BIEL has no money for marketing.
A Profitable BIEL is the Only Path for KW, PW, RS getting their Loans Repaid
An AS increase or a RS would open up more shares for Loan Conversions but it would Not Magically Produce Buyers for those Billions of Shares.
Wren the 'Usual Suspects' realize Synergy and the 975k units over 18 months is accurate, as publicly stated by BIEL, they will move on and bless another equity with their Opinions.
Thanks toohot, the BS is being laid down thick this week.
Perspective
BIEL's last full year of operations, 2021, saw 243.9 million shares of Dilution and a Net Loss of $289k. That may sound like a bad year to some but it is the best year BIEL has had in terms of lowest Dilution and lowest Net loss.
2020 - Dilution = 1.2 billion shares, Net Loss = $1.1 million
2019 - Dilution = 2.2 billion shares, Net Loss = $2.3 million
2018 - Dilution = 1.7 billion shares, Net Loss = $2.9 million
2017 - Dilution = 4 billion shares, Net Loss = $2.1 million
2016 - Dilution = 4.2 billion shares, Net Loss = $2.1 million
So, is BIEL currently where it wants to be? No.
Has BIEL made progress toward becoming a profitable company? Definitely Yes.
Wow, It is 2019 all over again
Does jimmy still have the pictures of toilets, train wrecks, sinking ships, tables full of pastries being consumed, ready to go?
If the Whelans are required to forfeit their "phoney" shares shouldn't the guy who received 629 million shares in 2020 for a 2 year $135k loan return those shares also?
You have the right attitude pinhigh and that is half of the battle for a speedy recovery.
Keep us posted.
It's called Advertising for a Sponsor to Fund Larger Trials
<<<<<<<<<<<<<< based on the treatment of 7 patients >>>>>>>>>>>>>>>>>>
And Dr Ilfeld/UCSD are very good at it having obtained tens of millions of dollars in DOD funding for Trials. The kind of Trials that get noticed by Doctors, the AMA and Health Insurance Companies.
LOL, "BIEL is not communicating with shareholders"
BIEL posts that Adcock Ingram, the 4th largest Pharma company in South Africa, has placed their first Reorder for ActiPatch and shows product being packed.
"BIEL posted Adcock ActiPatch Reorder too soon"
“Top 200 Pharmaceutical Companies in South Africa”
#1 Aspen
#2 Sun Pharmaceutical
#3 Allergan Pharmaceuticals
#4 Adcock Ingram
#5 Sanofi
#6 Novartis
#7 Pfizer
#8 Cipla
#9 Johnson & Johnson
#10 Merck & Co.
#11 Bayer (Pty) LTD
#12 Roche
Thanks Hawk, Nice to see details of this RecoveryRx Case Report
Noticed that Dr. Sree Koneru and Ken McLeod participated in this Report. This Report was totally funded by UCSD.
Acknowledgements
The authors would like to thank Sree Koneru, PhD
(BioElectronics Corporation, Frederick, MD; and Meraqui
Medical, Fremont, CA) and Kenneth J. McLeod, PhD
(Department of Systems Science and Industrial Engineering
and the Clinical Science and Engineering Research
Laboratory, Binghamton University, Binghamton, NY), for
reviewing much of the information in this manuscript for
technical accuracy.
Financial Support
Funding for this project provided by the University
California San Diego Department of Anesthesiology (San
Diego, California).
Must never have worked in a warehouse
There are two devices per level. one width wise one length wise.
Right side is18 high x 2 = 36, 2 rows deep = 72.
Left side has 36 in the rear row and 20 in the front = 56
Totaling 128 devices and it is obvious they are still filling the box. Shippers pay for weight and cubic feet so every cubic foot is used. That box will hold another 88 devices for a total of 216.
What we don't know is how many boxes that size are headed to Adcock who only began selling ActiPatch sometime after 8/25/2022 and is already Reordering in December. Keith mentioned that Adcock was not selling yet in the 8/25 Conference Call.
Not sure pinhigh, Keith stated that in the September Q-Submission post but not sure where else
"Very proud of our team, our Q-submission for our new Device RecoveryRX XTRA was received by the FDA. This platform has proven to reduce opioid consumption by 60% during the post op period and improve functionality and participation in PT&Rehab. As we have talked with potential partners, opportunity clearly exists in the orthopedic, breast augmentation and reconstruction spaces and all types of same day cases. We are continuing to disrupt the pain space with neuromodulation innovation, with no side effects, no interactions and efficacy. Thanks to our growing list of KOLS whose help has been incredible. #innovation #team #opportunity"
Thanks Gaffer, Very Professional Packaging for a Professional Pain Relief Product
Great move, listening to Partners and upgrading to the 'Book Box' ('Clamshell Box').
Keith on Linkedin
"After hearing feedback from new global partners we are proud to launch the new pack for RecoveryRX. The book box has tested really well and put a great visual to PEMF tech. Proven to spare the need for oral meds by 60% in post op cases. Down and dirty photos. #neuromodulation #painmanagement
#opioids"
https://www.linkedin.com/posts/keith-nalepka-8a6a9a124_neuromodulation-painmanagement-opioids-activity-7005934096279347200-NIvH/?utm_source=share&utm_medium=member_desktop
"The University of California San Diego has been ranked among the top 20 universities in the world, according to U.S. News & World Report's 2022-2023 Best Global Universities. In the newly released list, UC San Diego maintained its rank as No. 6 among the nation's top public colleges."
UCSD researcher Dr Ilfeld has a long list of research projects many funded by the Department of Defense and the Veterans Administration and he wants to do a Randomized Controlled Trial on Reducing Opioid Use with RecoveryRx :
Eliminating Post-Mastectomy Pain and Opioids with Percutaneous Cryoneurolysis: A Single-Administration, Non-Opioid, Non-Addictive, Multiple-Month Analgesic
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-21-PRMRP-CTA (PR212158)Sep 30, 2022 - Sep 29, 2026
Role: Principal Investigator
Description: $5,290,392
Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacologic Alternative for the Treatment of Postoperative Pain
Department of Defense Congressionally Directed Medical Research Programs, NIH-DoD-VA Pain Management Collaboratory—Pragmatic Clinical Trials Demonstration Projects (UG3/UH3)W81XWH-18-2-0009 (NH170005)May 1, 2018 - Apr 30, 2024
Role: Principal Investigator
Description: $6,971,337
Improving Postamputation Functioning by Decreasing Phantom Limb Pain and Opioid Use With Perioperative Continuous Peripheral Nerve Blocks: A Multicenter RCT
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Orthopaedic Research Program (PRORP)W81XWH-17-1-0671 (OR160012)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $2,847,215
Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial
Department of Defense Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP)W81XWH-17-2-0051 (PR160263)Sep 30, 2017 - Sep 29, 2023
Role: Principal Investigator
Description: $3,950,572
Treating Intractable Post-Amputation Phantom Limb Pain with Ambulatory Continuous Peripheral Nerve Blocks
Department of Defense Congressionally Directed Medical Research Programs Defense Medical Research and Development ProgramW81XWH-13-2-009Jan 25, 2012 - Dec 24, 2020
Role: Principal Investigator
Description: $2,617,000
https://profiles.ucsd.edu/brian.ilfeld
Yep TP, no recollection of praise for the 5 billion AS increase
AW did what he had to, keeping the BIEL doors open, it was painful but necessary.
The usual suspects twist away, some for over a decade, looking to destroy a company that wants to reduce the drug use of patients in pain.
Nice Hawk, 6 UCSD Anesthesiologists and 5 Surgeons lining up with Dr Ilfeld for use of RecoveryRx
Brian M Ilfeld
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
The Outcomes Research consortium, Cleveland, Ohio, USA.
Engy T Said
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
Rodney A Gabriel
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
The Outcomes Research consortium, Cleveland, Ohio, USA.
Brian P Curran
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
Matthew W Swisher
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
The Outcomes Research consortium, Cleveland, Ohio, USA.
Garth R Jacobsen
Department of Surgery, University of California San Diego, San Diego, California, USA.
Anne M Wallace
Department of Surgery, University of California San Diego, San Diego, California, USA.
Jay Doucet
Department of Surgery, University of California San Diego, San Diego, California, USA.
Laura M Adams
Department of Surgery, University of California San Diego, San Diego, California, USA.
George J Ventro
Department of Surgery, University of California San Diego, San Diego, California, USA.
Baharin Abdullah
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA
John J Finneran
Department of Anaesthesiology, University of California San Diego, San Diego, California, USA.
An AS increase can be approved by the BOD but it would not be a secret
Before a company can increase their AS they do need to amend their articles of incorporation.
This amendment is available to the public.
The OTC Markets also lists a current AS/OS in their "Security Details".
Below is the 2018 Amendment BIEL made to increase their AS,
"(3) The charter of the Corporation is hereby amended as follows:
FOURTH: The total number of shares of Common Stock that the Corporation shall have authority to issue is being increased from 20,000,000,000 (Twenty Billion) shares, par value $0.0001 per share, to 25,000,000,000 (Twenty-Five Billion) shares, par value $0.0001 per share."
There was only one Loan Conversion in 2022, All other Convertible Loans that matured in 2022 were Rolled Over
The one conversion was 326 million shares to St John's, Patricia Whelan, on 1/25/2022.
And what did St. John's do 10 days after that conversion? They started making new interest only loans to BIEL:
2/04/2022 - $15,000
2/09/2022 - $40,000
6/27/2022 - $10,000
9/15/2022 - $15,000
9/30/2022 - $10,000
BIEL only has 295 million shares remaining in their Authorized Shares so trying to scare people with significant dilution is a lame argument.
Some still don't get it
The only way KW, PW and RS get their loans repaid is when BIEL becomes a profitable business.
KW, over $6 million.
PW, over $3 million.
RS, over $800k.
There is no path to repayment through an AS increase unless BIEL is profitable. There is no market for billions of BIEL shares unless BIEL is producing millions of $$$ in profit.
There is no path to repayment through a RS unless BIEL is profitable. Pinkies that RS without profits quickly fall back to their pre RS SP.
EXIM Bank is first in line for any money recovered from a liquidation.
IMO, when BIEL is profitable those three big lenders will take their loan paybacks in cash from profits rather than diluting conversions.
The Undisputed Fact is that stating "no lock down since Q2" is Absolutely Not True
Anyone who follows current events is aware of the 11/24 Urumqi Apartment Fire that killed 10 people. These deaths were caused by China's Covid Lock Down policies which locked exit doors so that residents could not leave the building.
Residents in the city of 4 million, who had been under the Lock Down since August, flooded the streets with protests shouting, "end the Covid lockdown". This large of a protest happens so rarely in authoritarian China that it has been on every major news network around the world for the last 5 days.
As stated many times BIEL gets paid when product is delivered to its Partners not when consumer sales are made.
SAI's Canadian sales have been through 10 online stores. This was not a nationwide launch with their 10 "Powered By ActiPatch" products on the shelves of a thousand Canadian retailers.
It did prove that SAI is still interested in its "Powered By ActiPatch" product line which had been in a holding pattern for a year.
Must be living in an Alternate Universe
<<<<<<<<<<<< hasn't been a China Lockdown since Q2 >>>>>>>>>>>>>>
Covid lockdown protests break out in western China after deadly fire 11/26/2022
https://www.theguardian.com/world/2022/nov/26/covid-lockdown-protests-break-out-in-western-china-after-deadly-fire
China rocked by anti-lockdown protests of its harsh ‘zero COVID’ policies 11/27/2022
https://nypost.com/2022/11/27/china-rocked-by-anti-lockdown-protests-as-zero-covid-policies-remain/
How ‘forgotten,’ 110-day lockdown sparked China’s nationwide COVID protests 11/28/2022
https://fortune.com/2022/11/28/china-covid-protests-urumqi-xinjiang-lockdown-forgotten/
Material Events for Pinkies differ from SEC reporting companies
SAI has been selling their "Powered By ActiPatch" products for most of this year in Canada and yet we have not seen an official disclosure from BIEL about an SAI contract.
KW called it a "Contractual Obligation" not a "Goal", big difference
"Horok Lee it’s 975k units. I’m not promising you another party is going to execute on their contractual obligation"
"A contractual obligation is the legal obligation of each party to the contract to perform their obligations in the most fundamental sense. The contract parties‘ obligations and rights can be enforced by a law court."